Intellia Therapeutics (NTLA) Research & Development (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Research & Development data on file, last reported at $80.7 million in Q1 2026.

• On a quarterly basis, Research & Development fell 25.54% year-over-year to $80.7 million in Q1 2026; TTM through Mar 2026 was $361.2 million, a 21.97% decrease from a year earlier, with the FY2025 full-year figure at $388.9 million, down 16.61% from the prior year.
• Research & Development for Q1 2026 stood at $80.7 million, down from $88.7 million in the prior quarter.
• Over the last five years, Research & Development for NTLA reached as high as $133.1 million in Q1 2022 and fell as low as $80.7 million in Q1 2026.
• Historically, Research & Development has averaged $105.4 million across 5 years, with a median of $108.4 million in 2025.
• Across the five-year window, Research & Development surged 238.87% in 2022 and dropped 27.03% in 2023, its largest moves.
• Year by year, Research & Development stood at $100.0 million in 2022, then grew by 8.94% to $109.0 million in 2023, then climbed by 7.25% to $116.9 million in 2024, then decreased by 24.15% to $88.7 million in 2025, then dropped by 8.93% to $80.7 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $80.7 million in Q1 2026, $88.7 million in Q4 2025, and $94.7 million in Q3 2025.